Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1815)	6/19/2007 4:05:54 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

CVTX Is up for 4th day on a roll bigcharts.marketwatch.com It has continued to close its Mar7 DG. bigcharts.marketwatch.com It announced yesterday that it has issued new inducement stock options to 23 non-executive officers due to additional hiring. The Mar DG was when it announced that its ranolazine failed to meet its primary objectives in patients with coronary syndrome, although there were no safety concerns. CVTX seems to have a good amount of resistance at the $15 level. bigcharts.marketwatch.com But taking into account the $$ of institutional holders, it seems the R/R is OK at present levels. finance.yahoo.com The Nov 2000 H was $93.12 bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1815)	2/22/2008 10:48:08 AM
From: Jibacoa	Respond to of 3722

PARS is up for 3rd day on a roll.<g> It is trading at $0.66 up 17.8% & it has already more than doubled from its Jan2- Jan 17 dounle bottom at the $0.30 level.<g> bigcharts.marketwatch.com On Jan 3 it announced that it has completed a private placement of its 10% convertibles due Nov 2012 for $4M. The conversion price is $0.70/shr & interest is at the rate of 10%/yr. It said it could sell another $4M of similar debentures.<g> The stock has been trading around 0.6xBV & the insiders hold > 20%. The short ratio came down 40% & is < 0.5x its ADV PARS has a PIIb of Dextofisopam for the treatment of IBS.Its core technology focuses on development of synthetic cannabinoid compounds. Its Cannabinor is a CB2-selective receptor agonist candidate undergoing PIIa for pain. It has some other compounds targeting pain, MS,RA & IBD. The March 2000 H was $76.87 <g> bigcharts.marketwatch.com Bernard